vTv Therapeutics' stock doubles after raising $51 million from health care investors including JDRF
After nearly getting delisted from Nasdaq, High Point's vTv Therapeutics has raised $51 million in a private placement to continue testing a promising diabetes drug. Investors include a big name in Type 1 Diabetes research, JDRF. Here's how vTv will use the funding.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Lillian Johnson Source Type: news
More News: Diabetes | Diabetes Type 1 | Endocrinology | Funding | Health Management | Pharmaceuticals